Brought to you by 
Ariosa scraps IPO plans, chooses acquisition by Roche
10 Sep 2020
Executive Summary
For $400mm up front in cash, Roche Diagnostics Corp. acquired closely held Ariosa Diagnostics Inc., which produces early-stage maternal testing. Roche may also pay up to $225mm in earn-outs. Ariosa had filed for an IPO in March 2014.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ariosa scraps IPO plans, chooses acquisition by Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice